-+ 0.00%
-+ 0.00%
-+ 0.00%

Citius Oncology Expands LYMPHIR Launch Team Nationwide Ahead Of Full U.S. Deployment In August

Benzinga·07/21/2026 13:19:47
Listen to the news

Expanded commercial and medical affairs teams expected to be fully operational throughout the U.S. by August

CRANFORD, N.J., July 21, 2026 /PRNewswire/ -- Citius Oncology, Inc. ("Citius Oncology") (NASDAQ:CTOR), an oncology‑focused biopharmaceutical company and majority‑owned subsidiary of Citius Pharmaceuticals, Inc. ("Citius Pharma") (NASDAQ:CTXR), today provided an update on the commercial launch of LYMPHIR® (denileukin diftitox-cxdl), highlighting continued progress across market access, commercial execution, and physician adoption.

Citius Oncology has expanded its commercial organization to include 21 additional commercial field-based professionals and added eight medical science liaisons dedicated to supporting complex clinical practitioner engagement and patient care. All personnel are expected to be fully onboarded and deployed nationwide by August 2026.

The expansion of the commercial and medical teams was facilitated by the Company's May 2026 financing and implemented by EVERSANA, Citius Oncology's exclusive commercialization partner. EVERSANA also provides Citius Oncology with an integrated suite of operations services including medical information, pharmacovigilance, revenue cycle management, program management, data and analytics, channel management, and patient assistance.